Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Johnson & Johnson (NY: JNJ )

155.78 +0.61 (+0.39%)
Official Closing Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years
Following a lackluster big bank earnings, market participants now turn their attention to the unfolding week, expecting the trend to reverse. 
Via Benzinga
2 Healthcare Stocks to Buy Hand Over Fist This Month
They don't have the most exciting businesses, but they have a lot to offer nonetheless. 
Via The Motley Fool
3 High-Yield Dividend Stocks That Still Look Like Bargains
The prices of these reliable dividend payers haven't kept pace with the frothy stock market. 
Via The Motley Fool
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
MarketBeat Week in Review – 7/8 - 7/12
Stocks took investors on quite a ride this week, with the S&P 500 hitting a new record high, then falling back on Thursday before rallying to end the week 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
3 Key Earnings Reports To Watch Next Week
With the 2024 Q2 earnings season kicking into a much higher gear next week, there are several reports investors should keep on their radars, including those from Netflix, Taiwan Semiconductor, and... 
Via Talk Markets
3 Essential Stocks for Building a Recession-Proof Portfolio
Secure your portfolio with these three recession-proof stocks, chosen for their consistent performance and long-term growth. 
Via InvestorPlace
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
From Johnson & Johnson
Via Business Wire
3 Magnificent Dow Stocks That Are No-Brainer Buys for the Second Half of 2024
Among the Dow Jones Industrial Average's 30 time-tested components, there are three that stand out as phenomenal buys right now. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Undervalued Stocks Set to Outperform the Market in 2024
Discover the top three undervalued stocks poised for growth in the restaurant, pharmaceutical and footwear industries. 
Via InvestorPlace
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs
Johnson & Johnson is set to release its Q2 2024 earnings on July 17. Analysts estimate $22.29 billion in sales and an EPS of $2.71. 
Via Benzinga
Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing
Emergent BioSolutions and Janssen Pharmaceuticals settle disputes over SARS-CoV-2 vaccine manufacturing with a $50 million agreement, resolving all related claims and arbitration. 
Via Benzinga
Exposures COVID-19
7 Diversified Income Powerhouses for Lifelong Cash Flow
Explore diversified income stocks that provide stable cash flow and growth potential for long-term investors seeking lifelong income. 
Via InvestorPlace
3 Rock-Solid Income Machines to Hold for Decades
Hitch your ride with these three long-term income stocks with robust dividend yields, proven to boost portfolios with consistent growth 
Via InvestorPlace
3 Dividend Aristocrats Now Cheaper Than During the 2008 Financial Crisis
Explore opportunities in undervalued Dividend Aristocrats, featuring Genuine Parts, Johnson & Johnson, and Archer-Daniels-Midland. 
Via InvestorPlace
What's Going On With Johnson and Johnson Shares Friday?
In the last week, Johnson and Johnson announced positive results from two clinical trials and authorization from Health Canada for RYBREVANT in combination with platinum-based chemotherapy. 
Via Benzinga
Nasdaq vs. Dow Jones: A Detailed Breakdown of Stock Indexes
Nasdaq focuses on tech and growth stocks, offering high returns with higher volatility. Dow covers diverse sectors, providing steadier, lower-risk performance. 
Via MarketBeat
Topics Stocks
Exposures US Equities
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
Exposures Product Safety
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
7 Blue-Chip Cash Cows to Milk for Steady Income
Sometimes, you want to weather the storm rather than risk everything. For that, blue-chip income stocks can help. 
Via InvestorPlace
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
7 Safe Haven Stocks to Buy Before the Next Market Correction
Discover resilient safe haven stocks to weather economic fluctuations in restaurants, pharmaceuticals, household products, and retail. 
Via InvestorPlace
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
These Dividend Aristocrats all have payouts yielding three times or more the average yield of the S&P 500. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of... 
Via Benzinga
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
Court Rules Against Johnson & Johnson In Talcum Powder Cancer Study Case
A federal judge has dismissed a Johnson & Johnson subsidiary's lawsuit against Dr. Jacqueline Moline, who linked talc products to cancer. The ruling supports Moline's research and free speech rights... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
JNJ Should Rally Soon Or See 3 Swings Higher At Least
Johnson & Johnson (JNJ​​​​​​​) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. 
Via Talk Markets
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Ten of the Dow Jones Industrial Average stocks were up double digit percentage in the first half of 2024. A look at the best and worst performers. 
Via Benzinga
Topics Stocks
Exposures US Equities
"Rule Breaker Investing" Mailbag: Talking Stocks and Options
We also talk with Sean Milliken, managing director of The Motley Fool Foundation’s ImpactFool (IF) Fund. 
Via The Motley Fool
3 Retirement All-Stars for Steady Growth and Income
Retirement stocks lead the pack with steady dividends and strong growth potential. Invest smartly for a worry-free retirement. 
Via InvestorPlace
Topics Retirement
Exposures Pension
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.